A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces

A V Bazarov1, S Adachi, S F Li

  • 1Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, USA.

Cancer Research
|February 28, 2001
PubMed

Insights

A 50% reduction in c-Myc expression significantly impairs tumor transformation driven by Ras and Raf. This occurs independently of cell cycle defects, highlighting c-Myc

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Deregulation of c-Myc and mutations in Ras genes are common in human tumors.
  • c-Myc and oncogenic Ras are known to cooperate in malignant transformation, but the underlying mechanism remains unclear.
  • Previous studies on c-Myc's role in transformation used methods with potential artifacts.

Purpose of the Study:

  • To investigate the effect of a modest reduction in endogenous c-Myc expression on cellular transformation.
  • To elucidate the mechanism by which c-Myc and Ras cooperate in transformation.
  • To establish a stable and artifact-free system for studying c-Myc's role in transformation.

Main Methods:

  • Construction and utilization of a c-myc heterozygous (c-myc +/-) cell line via targeted homologous recombination.
  • Assessment of transformation susceptibility upon oncogenic Ras or Raf protein expression.
  • Genetic epistasis analysis to determine pathway interactions and examination of p27Kip1 regulation.
  • Investigation of cyclin D1, cyclin A, and cyclin D-Cdk4/6 complex activity.

Main Results:

  • A 50% reduction in c-Myc expression led to a >10-fold decrease in transformation susceptibility by Ras or Raf.
  • This defect in transformation was not due to generalized cell-cycle defects, as proliferation was only minimally affected.
  • c-Myc and Ras act via independent pathways converging on p27Kip1 regulation; c-Myc reduction impaired Ras-mediated p27 downregulation.
  • Ectopic expression of cyclin A rescued the transformation potential of c-myc +/- cells.

Conclusions:

  • Modest reduction in c-Myc significantly impairs oncogenic Ras/Raf-driven transformation, independent of major cell cycle defects.
  • c-Myc and Ras cooperate by regulating p27Kip1 levels, likely through modulation of cyclin D-Cdk4/6 activity.
  • Cyclin A is a downstream effector in the cooperative transformation pathway.
  • Therapeutic strategies targeting c-Myc levels may be effective, as transformation is sensitive to its expression, while significant reductions are tolerated by normal cells.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...